MARKET NEWS

Rhythm Pharmaceuticals Announces Sale of Priority Review Voucher for $100 Million
Ocuphire Pharma Initiates LYNX-1 Phase 3 Study Investigating Nyxol in Night Vision Disturbances
PHASTAR Announces Investment by Charterhouse Capital Partners
Akston Biosciences & LakePharma Announce Strategic Partnership to Manufacture Second-Generation COVID-19 Vaccine
Oncorus to Build GMP Viral Immunotherapy Clinical Manufacturing Facility 
Inozyme Pharma Announces Authorization to Proceed in US & UK With Phase 1/2 Clinical Trial
EyePoint Pharmaceuticals Announces $15.7-Million Equity Investment 

  FEATURED EDITORIAL

  COMPANY PROFILE

ARL Bio Pharma is a contract laboratory that provides analytical and microbiological testing to pharmaceutical companies and research scientists. Our laboratory is headquartered in Oklahoma City, Oklahoma, and serves over 3,000 clients nationwide. Since 1998, ARL has supported the industry-wide commitment to deliver high-quality therapeutic drug products by providing guidance and test services for all phases of the product lifecycle following USP, FDA, and ICH guidelines. Click here for more.

  EXCLUSIVE ONLINE CONTENT

ViGeneron Signs Global Development & Commercialization Agreement With Biogen

ViGeneron Signs Global Development & Commercialization Agreement With Biogen

ViGeneron GmbH recently announced a global collaboration and licensing agreement with Biogen Inc. to develop and commercialize gene therapy products based on adeno-associated virus (AAV) vectors to treat….

Radius Health Announces Commercial Agreement With Paladin Labs

Radius Health Announces Commercial Agreement With Paladin Labs

Radius Health, Inc. recently announced it has entered into definitive agreements with Endo Ventures Limited, a subsidiary of Endo International plc to register, commercialize, and distribute abaloparatide on an exclusive basis in….

University of Calgary Joins the Phase 2 Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients

University of Calgary Joins the Phase 2 Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients

Arch Biopartners Inc. RECENTLY announced the University of Calgary Cumming School of Medicine has joined the Phase 2 trial of its lead drug LSALT peptide (Metablok), targeting the prevention….

Ajinomoto Bio-Pharma Services & Revance Therapeutics Announce Manufacturing Agreement

Ajinomoto Bio-Pharma Services & Revance Therapeutics Announce Manufacturing Agreement

Ajinomoto Bio-Pharma Services and Revance Therapeutics, Inc. recently announced a strategic commercial manufacturing agreement for the supply of DaxibotulinumtoxinA for….

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

January 13 – Excipients
January 20 – Drug Delivery